학술논문
Predictors of venous thromboembolism in hospitalized patients with inflammatory bowel disease and colon cancer: A retrospective cohort study.
Document Type
Article
Author
Source
Subject
*INFLAMMATORY bowel diseases
*THROMBOEMBOLISM
*COLON diseases
*COLON cancer
*HOSPITAL patients
*CEREBRAL embolism & thrombosis
*
*
*
*
*
Language
ISSN
0049-3848
Abstract
Venous thromboembolism (VTE) in patients with inflammatory bowel disease (IBD) and colon cancer (CC) increases morbidity and mortality. Risk of thrombosis in IBD and CC is well established. Still, it remains unclear how interaction of thrombotic properties in patients with both diseases predict development of VTE. The Nationwide Inpatient Sample was sourced (2005–2014) for data on patients admitted with IBD-CC who developed VTE. The main outcome was predictors of VTE. Secondary outcomes were length of stay and total charge of admission. 7625 adults were admitted from 2005 to 2014 with a co-diagnosis of IBD and CC. 197 (2.6%) were coded to have VTE as a top three diagnosis. Multivariate logistic regression showed that black patients (11.9% vs 6.0%; aOR 2.04, 95% CI = 1.26–3.31, P < 0.004) and patients with metastatic disease (27.9% vs 16.7%; aOR 1.77, 95% CI = 1.27–2.47, P = 0.001) had higher odds of having VTE. Patients with uncomplicated diabetes (8.1% vs 15.5%; aOR 0.48, 95% CI = 0.28–0.84, P = 0.010) had lower odds. Obesity and anemia were significantly associated with VTE in univariate logistic regression, but lost significance after multivariate regression. Additionally, VTE was associated with increased length of stay (8.41 vs 6.87 days, P = 0.006) and admission cost ($64,388 vs $50,874, P = 0.010). Patients with IBD and CC likely have unique procoagulant properties that differ from patients with IBD or CC alone. Knowledge of these predictors can assist efforts to risk stratify IBC-CC patients, and can aid development of an individualized approach to DVT prophylaxis in this population. • Inflammatory bowel disease and colon cancer increase venous thromboembolism risk. • We investigate interaction of thrombotic properties in patients with both diseases. • Predictors of thrombosis were black race, metastasis, and uncomplicated diabetes. • Known thrombosis predictors, obesity and anemia, lost significance after regression. • Immunosuppressive use may be suppressing thrombotic effects of anemia and obesity. [ABSTRACT FROM AUTHOR]